Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Thérèse Dupin-Spriet"'
Autor:
Claude Brunet, Pascal Odou, Thérèse Dupin-Spriet, Bernard Gressier, Raymond Azar, Salmane Bah, Michel Luyckx, Nicolas Kambia, Thierry Dine
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 29:225-230
The disposition of naltrexone (NLT) (REVIA), an opioid antagonist intended for patients with impaired renal function and with severe intractable itching refractory to regular antipruritic therapy, was characterized. Hemodialysis effects on both effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0197eeb6bc6ceac861695ea39d9c56f3
https://doi.org/10.1007/bf03190603
https://doi.org/10.1007/bf03190603
Autor:
Patrick Wierre, Thérèse Dupin-Spriet
Publikováno v:
Therapies. 59:445-450
Resume Depuis octobre 2001, le systeme sanitaire australien prevoit, dans des circonstances predefinies, une prise en charge medico-pharmaceutique. Prescrite par un medecin, une visite est assuree par un pharmacien au domicile d’un patient ambulato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c39348c532d082ba9cf4510d5bf96d14
https://doi.org/10.2515/therapie:2004076
https://doi.org/10.2515/therapie:2004076
Publikováno v:
Drug Information Journal. 38:127-133
In block-randomized clinical trials where the treatments can be identified by their appearance or effects, knowledge of the length and composition of the blocks enables prediction of the nature of one or more treatments at the end of a block and may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83235f0d1503589166ae941b71e22783
https://doi.org/10.1177/009286150403800205
https://doi.org/10.1177/009286150403800205
Autor:
Alain Spriet, Thérèse Dupin-Spriet
Publikováno v:
Drug Information Journal. 30:661-667
Tables for sample size determination in parallel group dose-response clinical trials analyzed with second degree equations are presented in this paper. They were obtained by simulations and provide sample sizes to detect, with different power values,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a9b277b72e51f57752729ec15b432ca
https://doi.org/10.1177/009286159603000308
https://doi.org/10.1177/009286159603000308
Autor:
Alain Spriet, Thérèse Dupin-Spriet
Publikováno v:
Drug Information Journal. 28:1181-1186
In a global quality assurance environment, a system audit of pharmacovigilance is undertaken to check whether regulatory requirements and company quality policy are fulfilled. The most serious abnormalities in this field are: overlooking serious adve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a7b5925baf32e35fca69d70ff2ec567
https://doi.org/10.1177/009286159402800444
https://doi.org/10.1177/009286159402800444
Autor:
Thérèse Dupin-Spriet, Alain Spriet
Publikováno v:
Drug Information Journal. 28:787-790
Coding is necessary for summarizing adverse events in clinical trial reports. Although caricatural errors are easy to detect, more subtle errors are common. The importance of detecting subtle errors is discussed with particular reference to the asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc15ba739cc199280a80da3432d8301d
https://doi.org/10.1177/009286159402800314
https://doi.org/10.1177/009286159402800314
Autor:
Thérèse Dupin-Spriet, Alain Spriet
Publikováno v:
Drug Information Journal. 27:985-994
Trial planning should prevent errors, but imperfections are unavoidable. Transparency is necessary (listing and description of imperfections as well as rules to deal with imperfect data should be given in the trial report). Between purism and laxism,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cad6d4fc8dbb7d42af6ba32a31ab120
https://doi.org/10.1177/009286159302700408
https://doi.org/10.1177/009286159302700408
Autor:
Thérèse Dupin-Spriet, Alain Spriet
Publikováno v:
Drug Information Journal. 27:123-127
Inspection of investigational drugs used in clinical trials in France may cover good manufacturing practices (GMP) in the broad sense or for a given clinical trial. These inspections protect the subjects of biomedical research under French law. They
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b3fb421b2aaf89f07995fc8a0a601cb
https://doi.org/10.1177/009286159302700123
https://doi.org/10.1177/009286159302700123
Publikováno v:
Drug Information Journal. 27:135-143
Ensuring that investigational drugs are indistinguishable from placebos used in clinical trials is crucial to any study's success. The accuracy of double blinding, where neither the investigator or the patient can distinguish one study preparation fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39845857eafcaa4286081448bd53e11a
https://doi.org/10.1177/009286159302700125
https://doi.org/10.1177/009286159302700125